专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004032828A3 ANTI-CD20 ANTIBODY-DRUG CONJUGATES FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗CD20抗体药物治疗癌症和免疫缺陷病毒
公开(公告)号：WO2004032828A3
公开(公告)日：2006-04-27
申请号：PCT/US0323895
申请日：2003-07-30
申请人： SEATTLE GENETICS INC , WAHL ALAN F , SENTER PETER D , LAW CHE-LEUNG , CERVENY CHARLES G
发明人： WAHL ALAN F , SENTER PETER D , LAW CHE-LEUNG , CERVENY CHARLES G
IPC分类号： A61K39/395 , A61K47/48 , C07K16/46 , C07K16/00
CPC分类号： A61K47/6851 , A61K47/6849
摘要： The present invention relates to methods and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present methods comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides methods of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.
摘要翻译：本发明涉及用于治疗表达CD20的癌症和涉及CD20表达细胞的免疫疾病的方法和组合物。本发明的方法包括向受试者施用具有高效力和/或能够内化成CD20表达细胞的抗CD20抗体 - 药物偶联物。本发明还提供了包含这种缀合物的药物组合物和试剂盒。本发明还进一步提供了使用本发明的抗CD20抗体 - 药物共轭物的癌症和涉及CD20表达细胞的免疫疾病的组合疗法的方法和组合物。

2. 发明申请

WO2004006753A3 SGA-72M, A CANCER ASSOCIATED ANTIGEN, AND USES THEREOF 审中-公开
标题翻译： SGA-72M，一种癌症相关抗原及其用途
公开(公告)号：WO2004006753A3
公开(公告)日：2006-03-23
申请号：PCT/US0322113
申请日：2003-07-11
申请人： SEATTLE GENETICS INC , PETROZIELLO JOSEPH M , LAW CHE-LEUNG , WAHL ALAN F
发明人： PETROZIELLO JOSEPH M , LAW CHE-LEUNG , WAHL ALAN F
IPC分类号： C07K16/30 , C12Q1/68 , G01N33/574 , A61K38/00 , A61K49/00 , C07H21/04 , C07K14/00 , G01N33/53
CPC分类号： G01N33/57415 , A01K2217/05 , A01K2217/075 , A61K2039/505 , C07K16/3015 , C12Q1/6837 , C12Q1/6886 , C12Q2600/112 , C12Q2600/136 , C12Q2600/158 , G01N2500/04
摘要： The present invention relates to a gene and gene product, SGA-72M that is differentially expressed in cancer tissues and cell-lines. Suppression Subtractive Hybridization and microarray screening were used to screen for differential expression of SGA-72M in cancer tissues and cell-lines. Northern blot analysis and semi-quantitative RTPCR demonstrated over expression of SGA-72M in breast cancer tissue and breast cancer derived cell-lines. The gene is expressed as a 4.2kb mRNA. The SGA-72M cDNA comprises an open reading frame encoding 1342 amino acids. Monitoring expression levels of SGA-72M is useful for the diagnosis and prognosis of cancer as well as for evaluating the risk of developing certain types of cancers and the risk of metastasis of cancer. Antagonists that inhibit SGA-72M expression or activity are useful for the treatment of cancer. The SGA-72M polypeptide is associated with the plasma membrane and is on the cell surface of breast carcinoma cells and is a useful target for antibody-based therapeutics.
摘要翻译：本发明涉及在癌组织和细胞系中差异表达的基因和基因产物SGA-72M。使用抑制消减杂交和微阵列筛选筛选SGA-72M在癌组织和细胞系中的差异表达。 RNA印迹分析和半定量RTPCR证实在乳腺癌组织和乳腺癌来源的细胞系中SGA-72M的过表达。该基因表达为4.2kb mRNA。 SGA-72M cDNA包含编码1342个氨基酸的开放阅读框。监测SGA-72M的表达水平对于癌症的诊断和预后以及评估发展某些类型癌症的风险和癌症转移的风险是有用的。抑制SGA-72M表达或活性的拮抗剂可用于治疗癌症。 SGA-72M多肽与质膜相关并且在乳腺癌细胞的细胞表面上，并且是基于抗体的治疗剂的有用靶标。

3. 发明申请

WO2004073656A9 ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗-CD70抗体 - 药物偶联物及其用于治疗癌症和免疫紊乱的用途
公开(公告)号：WO2004073656A9
公开(公告)日：2005-09-01
申请号：PCT/US2004005247
申请日：2004-02-20
申请人： SEATTLE GENETICS INC , LAW CHE-LEUNG , WAHL ALAN F , SCHOLLER NATHALIE , PESTANO LINDA A
发明人： LAW CHE-LEUNG , WAHL ALAN F , SCHOLLER NATHALIE , PESTANO LINDA A
IPC分类号： A61K20060101 , A61K39/395 , A61K47/48 , A61K49/00 , C07K16/00 , C07K16/28
CPC分类号： A61K47/48561 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61K49/0041 , A61K49/0058 , C07K16/2875 , C07K2317/56 , C07K2317/565
摘要： Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
摘要翻译：公开了与细胞毒性剂，免疫抑制剂或其他治疗剂缀合的抗CD70抗体及其衍生物，以及包含抗体 - 和抗体衍生物 - 药物缀合物的药物组合物和试剂盒。还公开了用于治疗表达CD70的癌症和免疫学病症的方法，其包括向受试者施用公开的药物组合物。

4. 发明申请

WO2006044643A3 ANTI-CD70 ANTIBODY AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗CD70抗体及其用于治疗和预防癌症和免疫缺陷病毒
公开(公告)号：WO2006044643A3
公开(公告)日：2006-07-27
申请号：PCT/US2005036994
申请日：2005-10-14
申请人： SEATTLE GENETICS INC , LAW CHE-LEUNG , MCEARCHERN JULIE , WAHL ALAN F
发明人： LAW CHE-LEUNG , MCEARCHERN JULIE , WAHL ALAN F
IPC分类号： A61K39/395 , C12Q1/68 , G01N33/574
CPC分类号： C07K16/2875 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/732 , C07K2317/734
摘要： Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, systatic or immunosuppressive without conjugation to a therapeutic agenst, as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering to a subject the CD70-binding agent.
摘要翻译：公开了CD70结合剂，例如抗CD70抗体和衍生物，其诱导细胞毒性，系统性或免疫抑制，而不与治疗性结合物结合，以及包含抗体或衍生物的药物组合物和试剂盒。还公开了用于治疗和预防表达CD70的癌症和免疫学疾病的方法，包括向受试者施用CD70-结合剂。

5. 发明申请

WO2004024869A3 CANCER ASSOCIATED ANTIGENS, SGA-56M AND SGA-56MV, AND USES THEREOF 审中-公开
标题翻译：癌症相关抗原，SGA-56M和SGA-56MV及其用途
公开(公告)号：WO2004024869A3
公开(公告)日：2007-02-01
申请号：PCT/US0328676
申请日：2003-09-12
申请人： SEATTLE GENETICS INC , PETROZIELLO JOSEPH P , LAW CHE-LEUNG , YAMANE ANDREW K , WAHL ALAN F
发明人： PETROZIELLO JOSEPH P , LAW CHE-LEUNG , YAMANE ANDREW K , WAHL ALAN F
IPC分类号： C07K16/00 , C07K14/00 , C07K14/47 , G01N33/574
CPC分类号： G01N33/57415 , C07K14/4748
摘要： The present invention relates to nucleic and amino acid sequences of SGA-56M and variants thereof. An exemplary variant of SGA-56M is SGA-56Mv. SGA-56M and SGA-56Mv are differentially expressed in cancer tissues and transformed cell lines. In particular, these genes are expressed at elevated levels in breast cancer and lung cancer tissues and cell lines. The present invention is also directed to methods for diagnosing a cancer in a subject, determining the prognosis of a cancer patient, and/or monitoring the efficacy of a treatment regimen for a cancer patient. The present invention further provides methods for screening and identifying modulators (e.g., antagonists or agonists) of SGA-56M and/or SGA-56Mv expression and/or activity. Antagonists identified using the methods of the invention are useful for the treatment of cancer patients. Also encompassed by the present invention are compositions including nucleic and/or amino acid sequences of SGA-56M and SGA-56Mv or SGA-56M/SGA-56Mv modulators and a pharmaceutically acceptable carrier. Such compositions may be used to advantage to treat a subject with a cancer to ameliorate the symptoms of the cancer or reduce the cancer cell burden in the subject. These compositions may also be utilized to prevent or delay the onset of a cancer in a subject exhibiting a predisposition to developing a cancer.
摘要翻译：本发明涉及SGA-56M的核酸和氨基酸序列及其变体。 SGA-56M的示例性变体是SGA-56Mv。 SGA-56M和SGA-56Mv在癌组织和转化细胞系中差异表达。特别地，这些基因在乳腺癌和肺癌组织和细胞系中以升高的水平表达。本发明还涉及用于诊断受试者中的癌症的方法，确定癌症患者的预后和/或监测癌症患者的治疗方案的功效。本发明还提供筛选和鉴定SGA-56M和/或SGA-56Mv表达和/或活性的调节剂（例如拮抗剂或激动剂）的方法。使用本发明方法鉴定的拮抗剂可用于治疗癌症患者。本发明还包括包含SGA-56M和SGA-56Mv或SGA-56M / SGA-56Mv调节剂的核酸和/或氨基酸序列和药学上可接受的载体的组合物。这样的组合物可用于治疗患有癌症的受试者以改善癌症的症状或降低受试者的癌细胞负担。也可以利用这些组合物来预防或延迟患有发展为癌症倾向的受试者的癌症的发作。

6. 发明申请

WO2004073656A2 ANTI-CD70 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISORDERS 审中-公开
标题翻译：抗CD70抗体药物治疗及其用于治疗癌症和免疫缺陷病毒
公开(公告)号：WO2004073656A2
公开(公告)日：2004-09-02
申请号：PCT/US2004005247
申请日：2004-02-20
申请人： SEATTLE GENETICS INC , LAW CHE-LEUNG , WAHL ALAN F , SCHOLLER NATHALIE , PESTANO LINDA A
发明人： LAW CHE-LEUNG , WAHL ALAN F , SCHOLLER NATHALIE , PESTANO LINDA A
IPC分类号： A61K20060101 , A61K39/395 , A61K47/48 , A61K49/00 , C07K16/00 , C07K16/28 , A61K
CPC分类号： A61K47/48561 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61K49/0041 , A61K49/0058 , C07K16/2875 , C07K2317/56 , C07K2317/565
摘要： Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.
摘要翻译：公开了与细胞毒性，免疫抑制或其它治疗剂缀合的抗CD70抗体及其衍生物，以及包含抗体 - 和抗体衍生物 - 药物偶联物的药物组合物和试剂盒。还公开了用于治疗表达CD70的癌症和免疫学疾病的方法，包括向受试者施用所公开的药物组合物。

7. 发明申请

WO2005001038A3 RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：重组抗CD30抗体及其用途
公开(公告)号：WO2005001038A3
公开(公告)日：2006-02-02
申请号：PCT/US2004016916
申请日：2004-05-28
申请人： SEATTLE GENETICS INC , FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY , SENTER PETER D , DORONINA SVETLANA , TOKI BRIAN E
发明人： FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY , SENTER PETER D , DORONINA SVETLANA , TOKI BRIAN E
IPC分类号： A61K39/395 , A61K45/06 , A61K47/48 , A61P35/00 , C07K16/28 , C12N20060101 , C12P21/08
CPC分类号： C07K16/2878 , A61K39/39558 , A61K45/06 , A61K47/64 , A61K47/642 , A61K47/6849 , A61K2039/505 , C07K2317/24 , C07K2317/73
摘要： The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
摘要翻译：本发明涉及用于治疗霍奇金病的方法和组合物，其包括给予特征为结合CD30的能力的蛋白质，或与单克隆抗体AC10或HeFi-1竞争结合CD30，并对细胞生长抑制或细胞毒性作用霍奇金病细胞在没有效应细胞或补体的情况下。这些蛋白质包括单克隆抗体AC10和HeFi-1的衍生物。本发明的蛋白质可以是人，人源化或嵌合抗体; 此外，它们可以与细胞毒性剂如化学治疗药物缀合。本发明还涉及编码本发明蛋白质的核酸。本发明还涉及用于鉴定可用于治疗或预防霍奇金病的抗CD30抗体的方法。

8. 发明申请

WO0243661A3 RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：重组抗CD30抗体及其用途
公开(公告)号：WO0243661A3
公开(公告)日：2003-01-16
申请号：PCT/US0144811
申请日：2001-11-28
申请人： SEATTLE GENETICS INC , FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY B
发明人： FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY B
IPC分类号： C12N15/09 , A61K39/395 , A61K45/06 , A61K47/48 , A61P35/00 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , A61K39/40 , A61K39/42
CPC分类号： C07K16/2878 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K2317/24
摘要： The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
摘要翻译：本发明涉及用于治疗霍奇金病的方法和组合物，所述方法和组合物包含施用特征在于其与CD30结合的能力的蛋白质，或与单克隆抗体AC10或HeFi-1竞争结合CD30，并且发挥细胞抑制或细胞毒性作用霍奇金病细胞。这样的蛋白质包括单克隆抗体AC10和HeFi-1的衍生物。本发明的蛋白质可以是人类，人源化或嵌合抗体; 此外，它们可以与细胞毒剂例如化疗药物缀合。本发明还涉及编码本发明蛋白质的核酸。本发明还涉及鉴定用于治疗或预防何杰金氏病的抗CD30抗体的方法。

9. 发明申请

WO0243661B1 RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：重组抗CD30抗体及其用途
公开(公告)号：WO0243661B1
公开(公告)日：2003-03-06
申请号：PCT/US0144811
申请日：2001-11-28
申请人： SEATTLE GENETICS INC , FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY B
发明人： FRANCISCO JOSEPH A , RISDON GRANT , WAHL ALAN F , SIEGALL CLAY B
IPC分类号： C12N15/09 , A61K39/395 , A61K45/06 , A61K47/48 , A61P35/00 , C07K16/28 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , A61K39/40 , A61K39/42
CPC分类号： C07K16/2878 , A61K45/06 , A61K47/6849 , A61K2039/505 , C07K2317/24
摘要： The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.
摘要翻译：本发明涉及用于治疗霍奇金病的方法和组合物，其包括给予特征为结合CD30的能力的蛋白质，或与单克隆抗体AC10或HeFi-1竞争结合CD30，并对细胞生长抑制或细胞毒性作用霍奇金病细胞。这些蛋白质包括单克隆抗体AC10和HeFi-1的衍生物。本发明的蛋白质可以是人，人源化或嵌合抗体; 此外，它们可以与细胞毒性剂如化学治疗药物缀合。本发明还涉及编码本发明蛋白质的核酸。本发明还涉及用于鉴定可用于治疗或预防霍奇金病的抗CD30抗体的方法。

10. 发明专利

JP2013189472A Anti-cd70 antibody-drug conjugate, and use of the same for treatment of cancer and immune disorder 审中-公开
标题翻译：抗CD70抗体药物联合使用，同时用于治疗癌症和免疫缺陷病毒
公开(公告)号：JP2013189472A
公开(公告)日：2013-09-26
申请号：JP2013128242
申请日：2013-06-19
申请人： Seattle Genetics Inc , シアトルジェネティックス, インコーポレイテッド
发明人： LAW CHE-LEUNG , WAHL ALAN F , SCHOLLER NATHALIE , PESTANO LINDA A
IPC分类号： A61K39/395 , A61K20060101 , A61K45/00 , A61K47/48 , A61K49/00 , A61P35/00 , C07K16/00 , C07K16/28 , C07K16/46 , C12P21/08
CPC分类号： A61K47/48561 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61K49/0041 , A61K49/0058 , C07K16/2875 , C07K2317/56 , C07K2317/565
摘要： PROBLEM TO BE SOLVED: To provide an antibody-drug conjugate (ADC) and ADC derivatives for the treatment of CD70-expressing cancer and immunological disorders.SOLUTION: Anti-CD70 antibody combined with cytotoxic agent, immune suppressor or other therapeutic agents, and derivative of the same, and a drug composition containing antibody/drug composite or antibody derivative/drug conjugate and a kit are disclosed. Further, a method of treating cancer expressing CD70 or immunological disorder including a process of administering the disclosed drug composition to a body under test is disclosed. To be more concrete, a method for treating CD70-expressing cancer in a body under test including a process of administering an effective amount for the treatment of CD70/drug conjugate containing an antibody combining to CD70, wherein the drug is a cytotoxic agent or a cytostatic agent.
摘要翻译：要解决的问题：提供用于治疗表达CD70的癌症和免疫学疾病的抗体 - 药物偶联物（ADC）和ADC衍生物。解决方案：抗CD70抗体与细胞毒性剂，免疫抑制剂或其他治疗剂以及衍生物并且公开了含有抗体/药物复合物或抗体衍生物/药物偶联物和试剂盒的药物组合物。此外，公开了一种治疗表达CD70或免疫学疾病的癌症的方法，包括将所公开的药物组合物施用于被测体。更具体地说，一种用于治疗受试体内的CD70表达的癌症的方法，包括给予含有与CD70组合的抗体的CD70 /药物缀合物的有效量的方法，其中所述药物是细胞毒性剂或细胞抑制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式